Current Status of Pseudomonas aeruginosa Vaccine
Lessandra Michelim, Gregory Saraiva Medeiros and Alexandre P. ZavasckiAffiliation:
Infectious Diseases Service, University of Caxias do Sul - Hospital de Geral. 255 Prof Antonio Vignolli St, Caxias do Sul, 95070-561, Brazil.
AbstractPseudomonas aeruginosa is one of the major pathogens responsible for a wide variety of severe nosocomial and community acquired infections. Numerous vaccine candidates and several monoclonal antibodies have been developed over the past 40 years but only a few have reached clinical trials and none of these vaccine candidates has obtained market authorization. The understanding of P. aeruginosa pathogenesis and its virulence factors is essential in the identification of immunogens that can be used for a P. aeruginosa vaccine. This review summarizes the present status of vaccine development for this important pathogen.
Cystic fibrosis, Clinical trials, Hospital infections, Immunity, Pseudomonas aeruginosa, Vaccines.
Purchase Online Order Reprints Order Eprints Rights and Permissions